Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2022* -- Results Q4 2021 -- -0.48 --
03/01/2022* 16:30 EST Earnings Call Q4 2021 -- -- --
10/28/2021 -- Results Q3 2021 -0.13 -0.48 73.14%
10/28/2021 16:30 EST Earnings Call Q3 2021 -- -- --
07/29/2021 -- Results Q2 2021 -0.39 -0.50 22.00%
07/29/2021 16:30 EST Earnings Call Q2 2021 -- -- --
05/06/2021 -- Results Q1 2021 -0.55 -0.31 -80.33%
05/06/2021 16:30 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/01/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 10/28/2021
Beat/Miss Upgrade
Return Since 3.57%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.
URL https://www.travere.com
Investor Relations URL https://ir.travere.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2022
Last Earnings Release Oct. 28, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
57.60%
-1.87%
11.30%
7.40%
-37.25%
91.94%
13.89%
-11.28%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-2.11%
-28.70%
104.2%
56.44%
-16.14%
69.94%
13.41%
32.52%
-2.23%
-7.59%
-78.57%
4.09%
-76.55%
-0.62%
-24.70%
-53.18%
15.71%
-14.78%
-47.58%
48.46%
17.10%
-95.00%
-57.48%
77.60%
-17.69%
--
--
--
-61.60%
-79.11%
2.14K%
1.71%
24.32%
As of January 14, 2022.

Profile

Edit
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.
URL https://www.travere.com
Investor Relations URL https://ir.travere.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2022
Last Earnings Release Oct. 28, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F00001CY0W 424.00 USD 4.24%
PJP 10.16M USD 2.91%
BBP 388755.0 USD 2.16%
NIFE 65553.00 USD 1.64%
DCCRX 91.53M USD 1.21%
GSCZX 5.177M USD 0.57%
VVSCX 2.412M USD 0.49%
LUSOX 18872.00 USD 0.45%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits TVTX Tweets